[go: up one dir, main page]

DE60026144D1 - Benzamidformulierung mit histon-deacetylase-inhibitoraktivität - Google Patents

Benzamidformulierung mit histon-deacetylase-inhibitoraktivität

Info

Publication number
DE60026144D1
DE60026144D1 DE60026144T DE60026144T DE60026144D1 DE 60026144 D1 DE60026144 D1 DE 60026144D1 DE 60026144 T DE60026144 T DE 60026144T DE 60026144 T DE60026144 T DE 60026144T DE 60026144 D1 DE60026144 D1 DE 60026144D1
Authority
DE
Germany
Prior art keywords
deacetylase inhibitor
inhibitor activity
histon deacetylase
benzamide
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026144T
Other languages
English (en)
Other versions
DE60026144T2 (de
Inventor
Masahiko Ishibashi
Masahiro Sakabe
Ikuo Sakai
Tsuneji Suzuki
Tomoyuki Ando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of DE60026144D1 publication Critical patent/DE60026144D1/de
Publication of DE60026144T2 publication Critical patent/DE60026144T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
DE60026144T 1999-08-30 2000-08-29 Benzamidformulierung mit histon-deacetylase-inhibitoraktivität Expired - Lifetime DE60026144T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24244499A JP2001081031A (ja) 1999-08-30 1999-08-30 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP24244499 1999-08-30
PCT/EP2000/008421 WO2001016106A1 (en) 1999-08-30 2000-08-29 Benzamide formulation with histone deacetylase inhibitor activity

Publications (2)

Publication Number Publication Date
DE60026144D1 true DE60026144D1 (de) 2006-04-27
DE60026144T2 DE60026144T2 (de) 2006-11-16

Family

ID=17089193

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026144T Expired - Lifetime DE60026144T2 (de) 1999-08-30 2000-08-29 Benzamidformulierung mit histon-deacetylase-inhibitoraktivität

Country Status (32)

Country Link
US (1) US6638530B1 (de)
EP (1) EP1208086B1 (de)
JP (2) JP2001081031A (de)
KR (1) KR100712640B1 (de)
CN (1) CN1147472C (de)
AR (1) AR025434A1 (de)
AT (1) ATE318258T1 (de)
AU (1) AU773617B2 (de)
BG (1) BG65544B1 (de)
BR (1) BR0013648A (de)
CA (1) CA2382886C (de)
CZ (1) CZ301737B6 (de)
DE (1) DE60026144T2 (de)
DK (1) DK1208086T3 (de)
EE (1) EE05063B1 (de)
ES (1) ES2259289T3 (de)
HK (1) HK1046277B (de)
HR (1) HRP20020182B1 (de)
HU (1) HUP0203330A3 (de)
IL (2) IL148357A0 (de)
MX (1) MXPA02002090A (de)
NO (1) NO322532B1 (de)
NZ (1) NZ517520A (de)
PL (1) PL201274B1 (de)
PT (1) PT1208086E (de)
RU (1) RU2260428C2 (de)
SI (1) SI1208086T1 (de)
SK (1) SK287252B6 (de)
TW (1) TWI268778B (de)
UA (1) UA72541C2 (de)
WO (1) WO2001016106A1 (de)
ZA (1) ZA200201424B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
WO2002078669A1 (fr) * 2001-03-30 2002-10-10 Takeda Chemical Industries, Ltd. Solutions medicinales
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
KR20100107509A (ko) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (de) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
WO2003070691A1 (en) * 2002-02-21 2003-08-28 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
BR0308250A (pt) 2002-03-04 2005-01-11 Aton Pharma Inc Métodos de indução de diferenciação terminal
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003220119A1 (en) 2002-03-07 2003-09-22 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) * 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN100455564C (zh) * 2003-09-12 2009-01-28 深圳微芯生物科技有限责任公司 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
WO2005030705A1 (en) * 2003-09-24 2005-04-07 Methylgene, Inc. Inhibitors of histone deacetylase
CN1882529A (zh) * 2003-09-24 2006-12-20 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
EP1696898B1 (de) * 2003-12-02 2015-11-18 The Ohio State University Research Foundation Zn 2+ chelierende motiv-gebundene kurzkettige fettsäuren als neue klasse von histon-deacetylase-hemmern
WO2005059167A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for identifying histone deacetylase inhibitors
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
WO2007011626A2 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2007017728A2 (en) * 2005-08-05 2007-02-15 Orchid Research Laboratories Limited Novel heterocyclic compounds
US8598168B2 (en) 2006-04-07 2013-12-03 Methylgene Inc. Inhibitors of histone deacetylase
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
EP2135620A4 (de) 2007-03-28 2010-12-29 Santen Pharmaceutical Co Ltd Mittel gegen okuläre hypotonie mit einer verbindung zur histondeacetylasehemmung als wirkstoff
WO2009067808A1 (en) * 2007-11-27 2009-06-04 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
WO2009126662A1 (en) * 2008-04-08 2009-10-15 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac, an inhibitor of her-2, and a selective estrogen receptor modulator
JP5671451B2 (ja) * 2008-05-07 2015-02-18 メリオン・リサーチ・Ｉｉｉ・リミテッド ＧｎＲＨ関連化合物の組成物および調製プロセス
JP2011520891A (ja) * 2008-05-16 2011-07-21 チップスクリーン バイオサイエンシーズ エルティーディー． 強力かつ選択的なヒストン脱アセチル化酵素阻害剤としての６−アミノニコチンアミド誘導体
US8623853B2 (en) 2008-07-23 2014-01-07 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the NUT gene
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
EP3052662B1 (de) 2013-10-01 2019-05-15 The J. David Gladstone Institutes Zusammensetzungen, systeme und verfahren für genexpressionsrauschen-wirkstoffscreening und verwendungen davon
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
PL3317281T3 (pl) 2015-07-02 2020-11-02 Acerta Pharma B.V. Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
JP2019524879A (ja) * 2016-07-08 2019-09-05 ラネディス ファーマシューティカルズ リミテッド ライアビリティ カンパニー リソソーム蓄積症およびその他の単一遺伝子代謝疾患を処置および／または予防するための組成物および方法
WO2018222572A1 (en) * 2017-06-01 2018-12-06 Warner Babcock Institute For Green Chemistry, Llc Non-covalent derivatives and methods of treatment
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
WO2020218518A1 (ja) 2019-04-25 2020-10-29 富士製薬工業株式会社 医薬製剤およびその製造方法
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
WO2022091442A1 (ja) 2020-10-28 2022-05-05 株式会社キノファーマ ウイルス性腟周辺部疾患の予防又は治療のための医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ301044B6 (cs) * 1996-08-12 2009-10-21 Mitsubishi Tanabe Pharma Léciva obsahující amidové deriváty inhibující Rho kinázu
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
EP0977577B1 (de) * 1997-02-17 2006-08-16 ALTANA Pharma AG Zusammensetzungen zur behandlung von irds oder ards die 3-(calcopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤

Also Published As

Publication number Publication date
HK1046277A1 (en) 2003-01-03
CN1371366A (zh) 2002-09-25
MXPA02002090A (es) 2003-08-20
UA72541C2 (en) 2005-03-15
AU773617B2 (en) 2004-05-27
CZ301737B6 (cs) 2010-06-09
DK1208086T3 (da) 2006-06-19
BR0013648A (pt) 2002-05-07
EE200200097A (et) 2003-04-15
KR20020023424A (ko) 2002-03-28
DE60026144T2 (de) 2006-11-16
IL148357A0 (en) 2002-09-12
PT1208086E (pt) 2006-07-31
SI1208086T1 (sl) 2006-08-31
CZ2002724A3 (cs) 2002-07-17
SK2612002A3 (en) 2002-09-10
CN1147472C (zh) 2004-04-28
HUP0203330A3 (en) 2004-03-01
AU6841600A (en) 2001-03-26
JP2003508386A (ja) 2003-03-04
ATE318258T1 (de) 2006-03-15
IL148357A (en) 2006-12-10
SK287252B6 (sk) 2010-04-07
JP2001081031A (ja) 2001-03-27
BG65544B1 (bg) 2008-11-28
CA2382886A1 (en) 2001-03-08
NO20020952D0 (no) 2002-02-27
HK1046277B (zh) 2004-11-26
ES2259289T3 (es) 2006-10-01
EP1208086B1 (de) 2006-02-22
RU2260428C2 (ru) 2005-09-20
NO322532B1 (no) 2006-10-23
CA2382886C (en) 2009-06-09
HUP0203330A2 (hu) 2003-02-28
TWI268778B (en) 2006-12-21
US6638530B1 (en) 2003-10-28
KR100712640B1 (ko) 2007-05-02
HRP20020182A2 (en) 2004-02-29
PL353063A1 (en) 2003-10-06
ZA200201424B (en) 2002-11-27
NZ517520A (en) 2003-05-30
AR025434A1 (es) 2002-11-27
EP1208086A1 (de) 2002-05-29
EE05063B1 (et) 2008-08-15
WO2001016106A1 (en) 2001-03-08
HRP20020182B1 (en) 2007-08-31
NO20020952L (no) 2002-03-20
BG106439A (en) 2002-11-29
PL201274B1 (pl) 2009-03-31

Similar Documents

Publication Publication Date Title
DE60026144D1 (de) Benzamidformulierung mit histon-deacetylase-inhibitoraktivität
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
NO20012245D0 (no) Anthranilsyreamider og anvendelse derav som medikamenter
LTPA2018513I1 (lt) Pakeistieji ciklopentano ir ciklopenteno junginiai, tinkami panaudoti kaip neuraminidazės inhibitoriai
NO20012688D0 (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
DE50008416D1 (de) Klettverbindung für flächige gebilde
DK0832061T3 (da) Benzamidderivater og anvendelse deraf som vasopressin-antagonister
DK1207868T3 (da) Farmaceutiske tramadolsalte
EE200100504A (et) aP2 inhibiitoreid bifenüülrühmi sisaldav heterotsükliline ühend ja selle kasutamine
DK1163239T3 (da) Modificerede aminosyreamider som CGRP-antagonister
FI19992171A7 (fi) Sprinkleri
FI19992765A7 (fi) Suihkutuspää
NO994626L (no) Substituerte benzamider
PT864559E (pt) Compostos amino substituidos e sua utilizacao como substancias activas analgesicas
DK1558595T3 (da) Piperazinyl- og diazapanylbenzamider og -benzthioamider
NO994103D0 (no) Reverse hydroksamatderivater som metallproteaseinhibitorer
NO981178L (no) Vannl°selige korrosjonsinhibitorer
NO20013684D0 (no) Substituerte fenetylaminderivater
NO331228B1 (no) Anvendelse av en sammensetning som omfatter et ketotifensalt
EE200400104A (et) N-(3-butüün-1-üül)-N-hüdroksüuurea
PT1189929E (pt) Inibidores do factor viia
DE60018967D1 (de) Inierzierbare valnemulin formulierung
PT1074551E (pt) Fenilpirazois com actividade herbicida
IT1303916B1 (it) Difenilammine nonilate
EE200100084A (xx) NOS inhibiitorite uued farmatseutilised kasutusv�imalused

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE